# Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque

Study · id `cardio:ct-nct03169985` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03169985](<https://clinicaltrials.gov/study/NCT03169985>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03169985

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 280 participants.

## Technical summary

Registry record NCT03169985. Randomized; double masking; primary purpose treatment. Start 2017-07-12 (actual); primary completion 2027-01-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 280 participants (planned count; ClinicalTrials.gov record NCT03169985, source copy `cardio:ctgov-nct03169985-2025-07-16`, retrieved 2026-10-26)
- Started: 2017-07-12 (actual) (ClinicalTrials.gov record NCT03169985, source copy `cardio:ctgov-nct03169985-2025-07-16`, retrieved 2026-10-26)
- Primary completion: 2027-01-28 (anticipated) (ClinicalTrials.gov record NCT03169985, source copy `cardio:ctgov-nct03169985-2025-07-16`, retrieved 2026-10-26)
- Completion: 2027-01-28 (anticipated) (ClinicalTrials.gov record NCT03169985, source copy `cardio:ctgov-nct03169985-2025-07-16`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03169985, source copy `cardio:ctgov-nct03169985-2025-07-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03169985-2025-07-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque
- Acronym: Rosuzet-IVUS
- Condition: Coronary Artery Disease
- Intervention (Drug): Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day
- Intervention (Drug): Rosuvastatin 20 mg orally once a day
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER
- Collaborator: Hanmi Pharmaceutical co., ltd.
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)
- Registry lists this organization as a collaborator: Hanmi Pharmaceutical co., ltd. (`cardio:org-hanmi-pharmaceutical-co-ltd`)

## Provenance

Content hash: 36b92efafa391adde7b4f05a80b644a6b4a887d668d7108a3ee895bd02d350c1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
